DENVER, March 23, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that effective as of market open today, March 23, 2021, its common shares and warrants…

Source

Previous articlePT236 – Dr. Carl Hart – Drugs: Honesty, Responsibility, and Logic
Next articleMindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform (“Cope”); Cope Expected to Be World’s First in Vivo Psychedelic Benchmark Data Set